Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Justin Mirza

Orthopaedic Surgery Far Rockaway, NY Doctor of Osteopathy

NPI 1356648570 CMS profile 107254

51-15 Beach Channel Drive, Peninsula Hospital Center, Far Rockaway, NY 11691

Open in the dashboard

General payments

$1,883

54 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Justin Mirza of Far Rockaway, NY is reported in the CMS Open Payments database as having received $1,883 across 54 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 39th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $198 5
2024 General $159 5
2023 General $281 5
2022 General $220 10
2021 General $275 10
2020 General $286 7
2019 General $464 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Justin Mirza
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Justin Mirza were reported at $198. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Justin Mirza Orthopaedic Surgery median Middle half National median
2019 $464 $644 $140–$2,844 $163
2020 $286 $312 $75–$1,860 $114
2021 $275 $520 $117–$2,495 $132
2022 $220 $598 $128–$2,731 $149
2023 $281 $461 $128–$2,264 $160
2024 $159 $497 $134–$2,475 $164
2025 $198 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Horizon Therapeutics plc $222 12 payments
  2. Medtronic USA, Inc. $212 6 payments
  3. Relievant Medsystems, Inc. $188 3 payments
  4. Boston Scientific Corporation $167 3 payments
  5. Stryker Corporation $154 3 payments
  6. Djo, LLC $151 3 payments
  7. Gotham Surgical Solutions & Devices, Inc. $132 1 payment
  8. Medtronic, Inc. $114 5 payments
  9. Bioventus LLC $109 1 payment
  10. Flexion Therapeutics, Inc. $71 3 payments
  11. Other $364 14 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,883 54 payments
Products named General payments · program years 2019–2025
  1. Intracept Pain $188 3 payments
  2. Intracept Pain $188 3 payments
  3. Intracept Pain $188 3 payments
  4. Intracept Pain $188 3 payments
  5. INTELLIS Spinal Cord Neurostimulation $187 5 payments
  6. PENNSAID $178 9 payments
  7. Intracept Contains (1)Intracept RF Probe (2)Intracept Access Instruments_NMOD $167 3 payments
  8. INTELLIS Spinal Cord Neurostimulation $114 5 payments
  9. Exogen $109 1 payment
  10. Zilretta $71 3 payments
  11. Other $890 28 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

145

Median for Orthopedic Surgery: 203

Drug cost

$889

Median for Orthopedic Surgery: $1,433

Branded share of claims

55.2%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 80 $494
Celecoxib Generic 12 $273
Tramadol Hcl Generic 39 $73
Meloxicam Generic 14 $49

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 89 billing codes

Paid by Medicare

$160,854

Of which drugs: $5,952

Medicare patients

532

Average age 74

Services billed

2,743

322 women, 210 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 68%
Ischemic heart disease 37%
Diabetes 32%
Chronic kidney disease 21%
Osteoporosis 20%
COPD 17%
Cancer 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 218 314 $1,649
Injection, methylprednisolone acetate, 1 mg J1010 Office 14 740 $73

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

54 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record